Catalent (CTLT) has been the subject of several significant events. The stock has been acquired by
Novo Holdings in a deal valued at $16.5 billion. This acquisition is anticipated to expand
Novo Nordisk's supply of the drug, Wegovy. However, this news coincides with a notable increase in short interest for CTLT and few investors have experienced a loss of 47% over the past three years. There have been some major share sales from stakeholders such as
David Mcerlane and
Leonard Green & Partners L.P and some new significant investments from funds like
Alpine Associates Management Inc and
Caxton Associates LP. Catalent has recently faced a downgrade from Baird R.W. due to difficulty in finding valuation in a deal break. Nevertheless, the company's Q4 revenue and earnings surpassed estimates, with a gross margin increase. Despite delays in the filing of the annual report, Catalent has completed a $25 million expansion of its clinical supply facility in Schorndorf, Germany. Yet unresolved control lapses found by the US FDA at one of Catalent's plants potentially being sold to Novo added complications.
Catalent CTLT News Analytics from Wed, 10 Nov 2021 08:00:00 GMT to Sat, 28 Sep 2024 09:06:06 GMT -
Rating 4
- Innovation 0
- Information 7
- Rumor -3
